Edward Lang
Corporate Officer/Principal bei GYROSCOPE THERAPEUTICS HOLDINGS PLC
Profil
Edward Lang is currently the Chief Business Officer at Gyroscope Therapeutics Holdings Plc since 2019.
Prior to this, he was the Vice President-Corporate Affairs at Juno Therapeutics, Inc. from 2017 to 2018.
Mr. Lang completed his undergraduate degree at LaSalle University.
Aktive Positionen von Edward Lang
| Unternehmen | Position | Beginn |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Corporate Officer/Principal | 01.06.2019 |
Ehemalige bekannte Positionen von Edward Lang
| Unternehmen | Position | Ende |
|---|---|---|
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01.06.2018 |
Ausbildung von Edward Lang
| LaSalle University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
